Download Free Glaucoma Blood Flow And Medical Therapy Book in PDF and EPUB Free Download. You can read online Glaucoma Blood Flow And Medical Therapy and write the review.

Some people suffer from chronic, debilitating disorders for which no conventional treatment brings relief. Can marijuana ease their symptoms? Would it be breaking the law to turn to marijuana as a medication? There are few sources of objective, scientifically sound advice for people in this situation. Most books about marijuana and medicine attempt to promote the views of advocates or opponents. To fill the gap between these extremes, authors Alison Mack and Janet Joy have extracted critical findings from a recent Institute of Medicine study on this important issue, interpreting them for a general audience. Marijuana As Medicine? provides patientsâ€"as well as the people who care for themâ€"with a foundation for making decisions about their own health care. This empowering volume examines several key points, including: Whether marijuana can relieve a variety of symptoms, including pain, muscle spasticity, nausea, and appetite loss. The dangers of smoking marijuana, as well as the effects of its active chemical components on the immune system and on psychological health. The potential use of marijuana-based medications on symptoms of AIDS, cancer, multiple sclerosis, and several other specific disorders, in comparison with existing treatments. Marijuana As Medicine? introduces readers to the active compounds in marijuana. These include the principal ingredient in Marinol, a legal medication. The authors also discuss the prospects for developing other drugs derived from marijuana's active ingredients. In addition to providing an up-to-date review of the science behind the medical marijuana debate, Mack and Joy also answer common questions about the legal status of marijuana, explaining the conflict between state and federal law regarding its medical use. Intended primarily as an aid to patients and caregivers, this book objectively presents critical information so that it can be used to make responsible health care decisions. Marijuana As Medicine? will also be a valuable resource for policymakers, health care providers, patient counselors, medical faculty and studentsâ€"in short, anyone who wants to learn more about this important issue.
This is the sixth World Glaucoma Association Consensus. The relationship between ocular blood flow and glaucoma has been discussed for more than a century, and still it uniformly fuels debates at glaucoma meetings throughout the world. Clearly, the results of this report will have broad and significant impact on glaucoma research and clinical practice. The global faculty, consisting of leading authorities on the scientific and clinical aspects of ocular blood flow, have met in Fort Lauderdale on May 2, 2009 to discuss the reports and refine the consensus statements.
The volume reports lectures and discussions presented at the International Congress on Glaucoma, held in Rome on 2-4 February, 1996. The Congress has been designed to clarify and possibly to define the fundamental steps for managing glaucoma patients. "Decision making in therapy" does not mean that the conference sessions have been devoted to therapeutic problems only, even if semeiologic and diagnostic problems are pertinent when aimed at successful therapy. Actually, it is necessary to distinguish the onset of glaucoma from ocular hypertension, to decide if and how to start treatment and the methods to assess its effectiveness, to understand if the failure of medical therapy justifies surgery and, above all, if intraocular pressure is, in any case, the most important risk factor to treat. Particular relevance has been given to normal-pressure glaucoma, whose physiopatho logical and clinical characteristics are still highly controversial. Two round tables were devoted to the recent advances in the treatment of glaucoma, which aims at lowering intraocular pressure, directly improving the eye trophism and regenerating the areas damaged by the disease. All ophthalmologists, particularly the younger ones, have had the opportunity to capi talize on the experience and knowledge of distinguished experts from different parts of the world. This has been an invaluable and perhaps unique opportunity for all of us to express our doubts and to enhance our scientific background.
Preface Open angle glaucoma (OAG) is one of the leading causes of impaired vision worldwide. The pathogenesis of glaucomatous optic neuropathy remains poorly understood, and several pathogenic mechanisms are proposed to coexist. As the world population ages, OAG will become more prevalent and advances in the diagnosis and treatment of glaucomatous optic neuropathy are important to protect and improve the quality of life of our aging population. Treatment of OAG has been directed at lowering intraocular pressure (IOP) which is the only current therapeutic strategy available to patients with glaucoma. While a wide variety of studies have demonstrated that lowering IOP decreases the risk of glaucoma development and/or progression, many studies have also shown that some patients continue to lose vision despite significant lowering of IOP. There have been many attempts to elucidate the etiology for the deterioration in glaucomatous optic neuropathy despite low levels of IOP. Over the past several decades, deficits in the ocular circulation of patients with OAG have become well established and these may explain the continued progression of OAG patients despite lowered IOP. The purpose of the present publication is to provide an updated view of ocular blood flow and vascular dysregulation in OAG. The importance of the topic was demonstrated by the focus of the 2009 6th Consensus meeting of the World Glaucoma Association which focused entirely on blood flow deficits in patients with OAG. Although a great deal of knowledge on vascular risk factors in glaucoma has already been established, many questions remain. Do ocular blood flow deficits precede glaucoma progression? How does ocular perfusion pressure fit into the IOP and blood flow paradigm? What conclusions can be drawn from recent evidence showing the fluctuation of OAG risk factors including IOP, blood pressure and ocular perfusion pressure? We hope this update d current prospective will serve as a foundation for future investigations which will be designed to answer these and other important considerations in the management of glaucoma. Alon Harris, MS, PhD, FARVO Director of Clinical Research Lois Letzter Professor of Ophthalmology Professor of Cellular and Integrative Physiology
Glaucoma medical therapy has evolved with the advent of each new drug. This evolution has moved quickly and generated new information that clinicians need to understand, synthesize, and implement about medications that have specific benefits and risks for their glaucoma patients. This book aims to provide clinicians with an accessible guide to the current art and science of using clinically available drugs for the medical therapy of glaucoma. The contributors have attempted to present evidence-based information, while providing perspective from their clinical experience. In order to reflect the extensive changes that have occurred since the publication of the first edition in 1999, new chapters have been added about fixed combination drugs and the medical treatment of pediatric patients, and existing chapters have been thoroughly revised and updated. Glaucoma Medical Therapy will be a valuable reference for ophthalmologists in both practice and training, as well as for other practitioners who have clinical contact with glaucoma patients.